Trial Endpoints for Endemic Mycoses: Consensus Recommendations by the Mycoses Study Group Education and Research Consortium and European Confederation of Medical Mycology

BACKGROUND: Endemic mycoses, caused by Blastomyces, Coccidioides, Emergomyces, Histoplasma, Paracoccidioides, Sporothrix, and Talaromyces marneffei, represent an important global health challenge. Expanding endemic regions, climatic change, improved diagnostics, increased disease awareness, and an increasing at-risk population have contributed to rising case numbers. These infections affect both immunocompetent and immunocompromised hosts and exhibit marked clinical heterogeneity. Current treatment response guidance, established by the Mycoses Study Group and the European Organization for Research and Treatment of Cancer in 2008, are primarily tailored for invasive yeast and mold infections and are inadequate for endemic mycoses due to their complexity and heterogeneity. METHODS: An international, multidisciplinary expert panel convened through the Mycoses Study Group Education and Research Consortium and the European Confederation of Medical Mycology to develop consensus guidance for treatment response assessment in endemic mycoses. The process included a structured literature review, expert discussion, regulatory consultation, patient input, and public comment, culminating in consensus-based response criteria. RESULTS: The proposed guidance response criteria encompass clinical, mycologic, and radiologic assessments. CONCLUSIONS: The new criteria aim to improve the accuracy and standardize the assessment of treatment response, enabling comparison and pooling results across clinical trials while addressing the unique challenges posed by these diverse pathogens.

Authors

Institutions

Publication Details

Journal
Clinical Infectious Diseases
Published
2026-11-17
DOI
https://doi.org/10.1093/cid/ciag582
Citations
1
Primary Topic
Fungal Infections and Studies
Type
article
Field-Weighted Citation Impact
3.05

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Trial Endpoints for Endemic Mycoses: Consensus Recommendations by the Mycoses Study Group Education and Research Consortium and European Confederation of Medical Mycology

Thomas J. Walsh, Flávio Queiroz‐Telles, Nelesh Premapragasan Govender, Neil M. Ampel et al.
1 citations
Clinical Infectious Diseases
Fungal Infections and Studies
3.05
article

Trial Endpoints for Endemic Mycoses: Consensus Recommendations by the Mycoses Study Group Education and Research Consortium and European Confederation of Medical Mycology

Thomas J. Walsh, Flávio Queiroz‐Telles, Nelesh Premapragasan Govender, Neil M. Ampel, Ana Alastruey‐Izquierdo, Andrej Spec, Claudia E. Frola, Thuy P. Le, Emmanuel Roilides, Marisa H. Miceli, Nathan C. Bahr, Rosanne Sprute, Tom M Chiller, George R. Thompson, Alessandro Comarú Pasqualotto, Rob Purdie
article en
1 citations

Abstract

BACKGROUND: Endemic mycoses, caused by Blastomyces, Coccidioides, Emergomyces, Histoplasma, Paracoccidioides, Sporothrix, and Talaromyces marneffei, represent an important global health challenge. Expanding endemic regions, climatic change, improved diagnostics, increased disease awareness, and an increasing at-risk population have contributed to rising case numbers. These infections affect both immunocompetent and immunocompromised hosts and exhibit marked clinical heterogeneity. Current treatment response guidance, established by the Mycoses Study Group and the European Organization for Research and Treatment of Cancer in 2008, are primarily tailored for invasive yeast and mold infections and are inadequate for endemic mycoses due to their complexity and heterogeneity. METHODS: An international, multidisciplinary expert panel convened through the Mycoses Study Group Education and Research Consortium and the European Confederation of Medical Mycology to develop consensus guidance for treatment response assessment in endemic mycoses. The process included a structured literature review, expert discussion, regulatory consultation, patient input, and public comment, culminating in consensus-based response criteria. RESULTS: The proposed guidance response criteria encompass clinical, mycologic, and radiologic assessments. CONCLUSIONS: The new criteria aim to improve the accuracy and standardize the assessment of treatment response, enabling comparison and pooling results across clinical trials while addressing the unique challenges posed by these diverse pathogens.

Clinical Infectious Diseases
University of Maryland, Baltimore (US), University of Minnesota (US), Universidade Federal de Ciências da Saúde de Porto Alegre (BR), University of Arizona (US), St George's, University of London (GB), Duke University (US), University of Cologne (DE), Pham Ngoc Thach University of Medicine (VN), University of the Witwatersrand (ZA), Washington University in St. Louis (US), Aristotle University of Thessaloniki (GR), University of Exeter (GB), University of Michigan (US), Santa Casa Hospital (BR), Instituto de Salud Carlos III (ES), Düsseldorf University Hospital (DE), Integrated Oncology (United States) (US), Hospital Fernández (AR), Centro Nacional de Microbiologia (ES), Michigan Medicine (US), Centro de Investigación Biomédica en Red (ES), German Center for Infection Research (DE), Ippokrateio General Hospital of Thessaloniki (GR), Duke Medical Center (US), Hospital de Clínicas Universidade Federal do Paraná (BR), University of Minnesota Medical Center (US), Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases (DE), University Hospital Cologne (DE), University of California Davis Medical Center (US), Institute of Infection and Immunity (CA), MRC Centre for Medical Mycology (GB), Centro de Investigación Biomédica en Red Enfermedades Infecciosas (ES), Heinrich Heine University Düsseldorf (DE), Universidade Federal do Paraná (BR), University of California, Davis (US)
Pfizer, Gilead Sciences, Cidara Therapeutics, Government of the United Kingdom, National Institute for Health and Care Research, Astellas Pharma, Shionogi, Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen, National Institutes of Health, Centers for Disease Control and Prevention, Pan American Health Organization, National Institute of Allergy and Infectious Diseases
Good health and well-being
Openalex Percentile: Top 17%
Fungal Infections and Studies
3.05
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon